Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis
Authors
Keywords
Pioglitazone, Bladder cancer, Diabetes, Meta-analysis
Journal
TUMOR BIOLOGY
Volume 35, Issue 3, Pages 2095-2102
Publisher
Springer Nature
Online
2013-10-04
DOI
10.1007/s13277-013-1278-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis
- (2012) I. N. Colmers et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Peroxisome Proliferator-Activated Receptor Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes: Evidence from meta-analysis of 18 studies
- (2012) H. Zhang et al. DIABETES CARE
- Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
- (2012) A. Neumann et al. DIABETOLOGIA
- Benzodiazepine Use Possibly Increases Cancer Risk
- (2012) Chia-Hung Kao et al. JOURNAL OF CLINICAL PSYCHIATRY
- The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
- (2012) L. Azoulay et al. BMJ-British Medical Journal
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pioglitazone and Bladder Cancer: A population-based study of Taiwanese
- (2011) C.-H. Tseng DIABETES CARE
- Comment: Analyses Using Time-Dependent Pioglitazone Usage in Cox Models May Lead to Wrong Conclusions About Its Association With Cancer
- (2011) Xilin Yang et al. DIABETES CARE
- Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study
- (2011) J. D. Lewis et al. DIABETES CARE
- Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
- (2011) C. Piccinni et al. DIABETES CARE
- Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus
- (2011) Chia-Hsuin Chang et al. HEPATOLOGY
- DNMT3B polymorphisms and cancer risk: a meta analysis of 24 case–control studies
- (2011) Shimiao Zhu et al. MOLECULAR BIOLOGY REPORTS
- Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats
- (2011) Keiichiro Sato et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
- (2009) John Dormandy et al. DRUG SAFETY
- Effects of Pioglitazone, a Peroxisome Proliferator–Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat
- (2009) Shugo Suzuki et al. TOXICOLOGICAL SCIENCES
- Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARα+γAgonists
- (2009) Martin B. Oleksiewicz et al. PPAR Research
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Effects of PPAR agonists on proliferation and differentiation in human urothelium
- (2008) Claire L. Varley et al. EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
- Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
- (2008) Ronald A. Lubet et al. INTERNATIONAL JOURNAL OF CANCER
- Histopathology of the Urinary Bladders of Cynomolgus Monkeys Treated with PPAR Agonists
- (2008) Jerry F. Hardisty et al. TOXICOLOGIC PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started